Provided by Tiger Trade Technology Pte. Ltd.

Biogen

187.74
+3.802.07%
Volume:233.85K
Turnover:43.60M
Market Cap:27.54B
PE:21.36
High:188.58
Open:184.91
Low:184.91
Close:183.94
52wk High:202.41
52wk Low:110.04
Shares:146.70M
Float Shares:146.23M
Volume Ratio:1.63
T/O Rate:0.16%
Dividend:- -
Dividend Rate:- -
EPS(TTM):8.79
EPS(LYR):8.79
ROE:7.39%
ROA:6.14%
PB:1.51
PE(LYR):21.36

Loading ...

Biogen price target raised to $225 from $205 at Oppenheimer

TIPRANKS
·
Jan 30

FACTBOX-Global drugmakers rush to boost US presence as tariff threat looms

Reuters
·
Jan 30

U.S. RESEARCH ROUNDUP-Definium Therapeutics, Kenvue, Werner Enterprises

Reuters
·
Jan 30

Earning Preview: Biogen this quarter’s revenue is expected to decrease by 8.40%, and institutional views are cautious

Earnings Agent
·
Jan 30

Pharma Stocks Are Close to 'Breaking Out.' Earnings Could Set Them Free. -- Barrons.com

Dow Jones
·
Jan 29

Analysts Offer Insights on Healthcare Companies: Zimmer Biomet Holdings (ZBH), Dianthus Therapeutics (DNTH) and Biogen (BIIB)

TIPRANKS
·
Jan 28

FDA Grants Breakthrough Therapy Designation to Biogen’s Litifilimab for Cutaneous Lupus Erythematosus

Reuters
·
Jan 28

Biogen’s Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options

THOMSON REUTERS
·
Jan 28

Biogen - Amethyst Phase 3 Study Data Readout Expected in 2027

THOMSON REUTERS
·
Jan 28

Biogen Is Maintained at Neutral by Citigroup

Dow Jones
·
Jan 27

Citigroup Adjusts Price Target on Biogen to $185 From $180, Maintains Neutral Rating

MT Newswires Live
·
Jan 27

Analysts Have Conflicting Sentiments on These Healthcare Companies: Enovis (ENOV), Guardian Pharmacy Services, Inc. Class A (GRDN) and Biogen (BIIB)

TIPRANKS
·
Jan 27

Biogen : Citigroup Raises Target Price to $185 From $180

THOMSON REUTERS
·
Jan 27

U.S. RESEARCH ROUNDUP-AMETEK, Stryker, Zimmer Biomet Holdings

Reuters
·
Jan 27

Eisai, Biogen announces FDA accepted to review the sBLA for lecanemab-irmb

TIPRANKS
·
Jan 26

BRIEF-Eisai & Biogen Say U.S. FDA Accepts Leqembi Supplemental Biologics License Application As Subcutaneous Starting Dose For Treatment Of Early Alzheimer's Under Priority Review

Reuters
·
Jan 26

FDA Accepts Leqembi® Iqliktm (Lecanemab-Irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Priority Review

THOMSON REUTERS
·
Jan 26

Biogen Inc. Stock Underperforms Friday When Compared To Competitors

Dow Jones
·
Jan 24

Wedbush Raises Price Target on Biogen to $178 From $143, Keeps Neutral Rating

MT Newswires Live
·
Jan 23

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Teleflex (TFX) and Biogen (BIIB)

TIPRANKS
·
Jan 22